Does Rallies show 13F holders for PSTV?

Yes. Rallies tracks hedge fund and 13F ownership data for PSTV, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PSTV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PSTV. It does not provide personalized investment advice.

PSTV (PLUS THERAPEUTICS, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

PLUS THERAPEUTICS, Inc. Common Stock (PSTV) is a publicly traded Healthcare sector company. As of May 19, 2026, PSTV trades at $5.89 with a market cap of $36.03M and a P/E ratio of -19.12. PSTV moved +3.85% today. Year to date, PSTV is -57.91%; over the trailing twelve months it is -44.38%. Its 52-week range spans $2.90 to $57.75. Analyst consensus is strong buy with an average price target of $38.00. Rallies surfaces PSTV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PSTV stock?

Hedge funds tracked by Rallies that own PSTV include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for PLUS THERAPEUTICS, Inc. Common Stock.

PSTV Key Metrics

Key financial metrics for PSTV
Metric	Value
Price	$5.89
Market Cap	$36.03M
P/E Ratio	-19.12
EPS	$-0.29
Dividend Yield	0.00%
52-Week High	$57.75
52-Week Low	$2.90
Volume	96.84K
Avg Volume	0
Revenue (TTM)	$5.21M
Net Income	$-22.39M
Gross Margin	0.00%

Top Hedge Funds Holding PSTV

Citadel Advisors holds 18.28K shares of PSTV, changed +70.73% as of Jun 30, 2024.
Renaissance Technologies holds 17.40K shares of PSTV, changed -47.27% as of Mar 31, 2024.

Latest PSTV News

Plus Therapeutics Deploys AI Platform for CNS Oncology Data Integration Starting 2026 — May 19, 2026
Plus Therapeutics Raises $15M, Expands CNSide Coverage to 81M Lives, Gains FDA Orphan Status — May 15, 2026
Plus Therapeutics Secures Medicare Enrollment, Unlocks Billing for CNSide Assay to 35M Patients — May 7, 2026
Plus Therapeutics Expands CNSide Coverage by 6 Million Lives to 81 Million with Blue Shield Deal — Apr 28, 2026
Plus Therapeutics Initiates SpectronRx Manufacturing for REYOBIQ Late-Stage Trial Readiness — Apr 23, 2026

Recent PSTV Insider Trades

Sims Andrew John Hugh MacIntyre bought 20.00K (~$10.20K) on Nov 4, 2025.
Lenk Robert P bought 110.00K (~$53.78K) on Aug 22, 2025.
Hawkins Richard J bought 4.00K (~$6.00K) on Sep 13, 2024.

PSTV Analyst Consensus

5 analysts cover PSTV: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.00.

Common questions about PSTV

Who owns PSTV stock?: Hedge funds tracked by Rallies that own PSTV include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for PLUS THERAPEUTICS, Inc. Common Stock.
Does Rallies show 13F holders for PSTV?: Yes. Rallies tracks hedge fund and 13F ownership data for PSTV, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PSTV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PSTV. It does not provide personalized investment advice.